MassDevice Q&A: John Abele, Part II

June 10, 2010 by Brad Perriello

Boston Scientific Corp. co-founder John Abele, in the second installment of a lengthy interview, on the early days with Peter Nicholas, his take on demands for increased transparency and his frustration with some of the company's recent low points.

MassDevice Q&A: John Abele, Part II

Boston Scientific Corp. (NYSE:BSX) co-founder John Abele told us about the origins of the medical device giant in the first installment of a lengthy chat with MassDevice, detailing its start in the basement of a famed Czech mystic's lab in a Catholic church rectory.

In the second installment, Abele touches on how he and co-founder Peter Nicholas engineered the Boston Scientific's launch, how his involvement with the Natick, Mass.-based company evolved over the years and how being a "cheap son of a bitch" helped drive creativity and innovation in the early days.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Comments

Features

ResMed CEO Mick Farrell tells MassDevice.com about the history of ResMed, its sleep apnea devices and the future of treating chronic disease.

Dr. Robert Greenberg, founder & CEO of Second Sight Medical, chats with MassDevice.com in advance of his appearance at the Big 100 West to discuss the Argus II 'bionic eye.'

CEO Josh Kornberg tells MassDevice.com about cleaning house and how bad news for rival Stryker Corp. is helping to reinvigorate Skyline Medical.

In this MassDevice.com podcast, we speak with Glooko CEO Rick Altinger about the company's mobile diabetes management application for smartphones and how it has the potential to change the spectrum of care for one of the world's most common chronic diseases.

Renal denervation has won a lot of praise as a potential solution for patients with resistant hypertension, but the excessive celebration of early clinical trial results may be setting everyone up for a major letdown and a harsh backlash. This week cardiologists at the Transcatheter Cardiovascular Therapeutics conference, including those involved with Medtronic's and Boston Scientific's clinical trials, warned of the dangers of exaggeration.

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp